| 邓立军,张淑琴,魏 进,吴 丹,丁 亿.阿托伐他汀联合双抗血小板治疗对脑梗死患者疗效及对血清炎性因子水平的影响[J].,2017,17(31):6107-6110 |
| 阿托伐他汀联合双抗血小板治疗对脑梗死患者疗效及对血清炎性因子水平的影响 |
| Effect of Atorvastatin combined with Double Antiplatelet Therapy on Patients with Cerebral Infarction |
| 投稿时间：2017-07-05 修订日期：2017-07-28 |
| DOI：10.13241/j.cnki.pmb.2017.31.025 |
| 中文关键词: 阿托伐他汀 双抗血小板疗法 脑梗死 神经功能缺损 血清炎性因子 |
| 英文关键词: Atorvastatin Double antiplatelet therapy Cerebral infarction Neurological impairment Serum inflammatory factor |
| 基金项目: |
|
| 摘要点击次数: 260 |
| 全文下载次数: 189 |
| 中文摘要: |
| 摘要 目的：观察阿托伐他汀联合双抗血小板治疗对脑梗死患者脑血管事件复发率、神经功能缺损、血清炎性因子水平的影响，探讨其疗效和安全性。方法：选择2014年6月到2016年6月我院收治的脑梗死患者110例，按照随机数字表分为实验组和对照组，每组55例。两组患者均接受脑梗死常规治疗，对照组服用阿托伐他汀和阿司匹林，实验组服用阿托伐他汀、阿司匹林和氯毗格雷。在治疗前和治疗后2周、4周分别采用美国国立卫生研究院卒中量表（NIHSS）对患者神经功能缺损程度进行评分，检测血清炎性因子白细胞介素-6（IL-6）、白细胞介素-8（IL-8）和肿瘤坏死因子-α（TNF-α）水平，随访4周并统计脑血管事件复发率。结果：两组患者治疗2周、4周后NIHSS评分均低于治疗前（P＜0.05），且实验组低于对照组（P＜0.05）。两组患者治疗2周、4周后血清IL-6、IL-8和TNF-α均低于治疗前（P＜0.05），治疗4周后，实验组血清IL-6、IL-8和TNF-α水平均明显低于对照组（P＜0.05）。实验组患者脑血管事件复发率低于对照组，但差异无统计学意义（P>0.05）。结论：阿托伐他汀联合双抗血小板疗法具备一定的抗炎作用，有助于脑梗死患者神经功能缺损恢复，且脑血管事件复发率低，值得临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of Atorvastatin combined with double antiplatelet therapy on the recurrence rate of cerebral vascular events, neurological impairment and serum inflammatory factor level in patients with cerebral infarction, and to explore its efficacy and safety. Methods: A total of 110 patients with cerebral infarction, who were treated in Affiliated Hospital of Jianghan Uni- versity from June 2014 to June 2016, were selected and randomly divided into experimental group(n=55) and control group(n=55). The two groups received routine treatment of cerebral infarction; the control group received Atorvastatin and Aspirin, and the experimental group received Atorvastatin, Aspirin and Clopidogrel. Before treatment, 2 weeks and 4 weeks after treatment, the neurological impairment of patients was evaluated by national institutes of health stroke scale (NIHSS) scores. The levels of serum inflammatory factors such as interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor-α (TNF-α) were detected. All the patients were followed up for 4 weeks, and the recurrence rate of cerebral vascular events was recorded. Results: The NIHSS scores of two groups 2 weeks and 4 weeks after treatment were lower than those before treatment (P<0.05), and the NIHSS scores of experimental group was lower than that of the control group (P<0.05). The levels of serum IL-6, IL-8 and TNF-α in the two groups 2 weeks and 4 weeks after treatment were lower than those before the treatment (P<0.05). The levels of serum IL-6, IL-8 and TNF-α in the experimental group were lower than those in the control group 4 weeks after treatment (P<0.05). The recurrence rate of cerebral vascular events in the experimental group was lower than that in the control group, but the difference was not statistically significant (P>0.05). Conclusion: Combination of Atorvastatin and double antiplatelet therapy has certain anti-inflammatory effects, and it is helpful to the recovery of neurological impairment in patients with cerebral infarction. The recurrence rate of cerebral vascular events is low, so it is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
